Lupin has received USFDA approval for its generic Loteprednol Etabonate ophthalmic suspension, a treatment for seasonal allergic conjunctivitis. The product is a generic equivalent to Alrex ophthalmic suspension and is expected to generate USD 29.1 million in annual sales.
New Delhi, Dec 27 (PTI) Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic Loteprednol Etabonate ophthalmic suspension indicated for temporary relief of seasonal allergic conjunctivitis.
The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Loteprednol Etabonate ophthalmic suspension, 0.2 per cent, Lupin said in a regulatory filing.
It is a generic equivalent to the reference listed drug (RLD) Alrex ophthalmic suspension, 0.2 per cent of Bausch & Lomb Inc.
The product will be manufactured at Lupin's Pithampur facility in India, the company added.
Loteprednol Etabonate ophthalmic suspension, 0.2 per cent, is indicated for the temporary relief of signs and symptoms of seasonal allergic conjunctivitis.
It had estimated annual sales of USD 29.1 million in the US market, Lupin said citing IQVIA MAT October 2023 data.
Home » Market News » Lupin Gets USFDA Approval for Generic Loteprednol Etabonate
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback